BASF's Two-Front Strategy: Evonik Talks and Ag IPO Prep Collide
Published on 09/27/2026 at 15:21 | Editorial boerse-global.de
BASF has set two very different clocks ticking at once. One is counting down to a capital markets debut for its agricultural arm; the other began last week, when confirmation of exploratory talks with RAG-Stiftung and Evonik Industries over a possible takeover sent shareholders heading for the exits.
The market's verdict on the Evonik overture was swift. BASF shares shed 2.6% on Friday, closing at EUR 50.89, as investors weighed what a full acquisition of the specialty chemicals group would mean for a company already mid-way through a sweeping portfolio overhaul.
An Uninvited Approach With No Strings Attached
BASF was careful to stress that the outcome of the exploratory discussions remains entirely open. Evonik, for its part, confirmed to media that it had received an unsolicited approach regarding a voluntary public takeover offer for all of its shares — while making clear that no talks are currently underway.
The timing is awkward. Roughly two weeks before news of the Evonik soundings broke, BASF had mandated Citi, Deutsche Bank, Goldman Sachs and J.P. Morgan as global coordinators for the planned flotation of its Agricultural Solutions division, a listing being prepared for no later than mid-2027. Pursuing a large specialty chemicals deal in parallel raises pointed questions about strategic priorities and how the group intends to allocate capital.
The Financing Question Nobody Can Answer Yet
What a combination would actually cost — and how it could be structured — sits at the heart of the uncertainty. Evonik is an established specialty player, and swallowing it whole would tie up substantial financial resources. Such a transaction would either push BASF's leverage noticeably higher or require extensive capital measures.
Should investors sell immediately? Or is it worth buying BASF?
RAG-Stiftung's role as a major Evonik shareholder adds another layer. Any deal would hinge on a workable compromise over valuation and the future shape of the combined business. With only non-binding soundings on the table and no formal negotiations, the market has little to go on when judging the odds of a deal ever being struck. Investors must also decide whether the synergy potential of a larger specialty chemicals operation justifies the considerable integration and execution risks.
What Success Would Look Like
In the optimistic reading, BASF uses the soundings to explore value-accretive options for its portfolio without overcommitting financially. A deal struck on disciplined terms would meaningfully expand the group's position in higher-margin specialty chemicals, reducing its reliance on classic base chemicals and hardening operations against economic swings.
An orderly process could also dovetail with the ongoing cleanup of the existing portfolio. Combined with the planned partial flotation of Agricultural Solutions by mid-2027, it would offer a chance to fundamentally reorient the group toward more profitable segments. If management gets the balance right and avoids a costly bidding war, greater strategic clarity could rebuild confidence over the medium term. The stock is up 15% since the start of the year despite the recent pullback — a sign of underlying resilience.
JPMorgan Stays Cold on the Idea
Not everyone is convinced. Analyst Chetan Udeshi of JPMorgan kept his "Underweight" rating unchanged on September 24, taking a critical view of BASF's potential interest in Evonik. He also flagged that tailwinds from the special economic boost tied to the Middle East war are fading. An expensive acquisition at a moment when that cyclical support is ebbing — against persistent structural challenges in the European chemicals industry — carries the risk of significant value destruction.
Should BASF escalate its plans, a protracted stretch of uncertainty looms. A formal offer carrying a hefty valuation premium would likely spark fears among market participants about balance sheet strain and possible rating downgrades. Udeshi has likewise criticized external acquisition plans more broadly, calling a takeover interest in Evonik strategically questionable on the grounds that better alternatives exist, and continues to recommend selectivity across the European chemicals sector.
Ag Unit Reshuffles Its Leadership Ranks
While the Evonik question hangs in the air, BASF is pressing ahead with the operational groundwork for its agricultural spinoff. Agricultural Solutions announced far-reaching personnel and organizational changes on Thursday. In the US business, Leta LaRush takes over as Senior Vice President USA effective October 1, 2026. A new global structure is set to take effect on January 1, 2027.
The internal tightening is widely seen as a key building block to position the segment for future capital markets steps and to bring order to its structures in core markets — complementing the bank mandates arranged roughly two weeks earlier.
A Stronger Balance Sheet Behind the Restructuring
Operationally, BASF can lean on improved earnings. A little over a month ago the group raised its full-year guidance and is targeting EBITDA before special items of between EUR 6.9 billion and EUR 7.7 billion. The free cash flow target range was left unchanged.
BASF at a turning point? This analysis reveals what investors need to know now.
Earlier divestments are helping fund the reshaping. More than a month ago, BASF completed the sale of its Coatings business to Carlyle, a move that generated a disposal gain of EUR 3.5 billion in the second quarter of 2026 and bolstered the balance sheet on which management is now driving the agricultural unit's restructuring.
Operational Setbacks Add to the Noise
There are reminders, too, that the existing asset base demands attention. On September 21, BASF reported a deflagration during maintenance work at its Ludwigshafen North site, in which two employees of an external contractor suffered burn injuries. Such operational friction underscores how binding the challenges at existing sites remain.
The EUR 50 Line and the Next Catalyst
For now, the stock's broader recovery of recent months stays intact as long as it can hold above the psychologically important EUR 50 mark. A sustained break below it would risk amplifying pressure from the takeover uncertainty, likely prompting investors to extend their wait-and-see stance until management clarifies its intentions on Evonik.
A fixed date already looms: on October 28, 2026, BASF publishes its third-quarter 2026 report. That occasion gives the leadership a chance to update market participants on operating earnings and to address how it intends to proceed with the soundings. Until then, reliable news on the talks with RAG-Stiftung is likely to be the single biggest driver of the share price.
Ad
BASF Stock: New Analysis - 27 September
Fresh BASF information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
